ConductScience.org, home

Paper8306370

7-Allyl-8-oxoguanosine (loxoribine) inhibits the metastasis of B16 melanoma cells and has adjuvant activity in mice immunized with a B16 tumor vaccine.

Pope BL and 4 others. Cancer Immunol Immunother, 1994. Cited by 22 papers, by iCite.

Cite this record

ConductScience Library. 7-Allyl-8-oxoguanosine (loxoribine) inhibits the metastasis of B16 melanoma cells and has adjuvant activity in mice immunized with a B16 tumor vaccine. Papers, record 8306370. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8306370

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
7-Allyl-8-oxoguanosine (loxoribine) inhibits the metastasis of B16 melanoma cells and has adjuvant activity in mice immunized with a B16 tumor vaccine.
PubMed
Journal
Cancer Immunol Immunother
PubMed
Year
1994
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
22
iCite
Relative citation ratio, by iCite
0.46
iCite
Revised in PubMed
2024-04-26
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pope BLB L
2Sigindere JJ
3Chourmouzis EE
4MacIntyre PP
5Goodman MGM G

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
GuanosineMajor topic
Melanoma, ExperimentalMajor topic
Adjuvants, Immunologic
Animals
G(M1) Ganglioside
Interleukin-2
Lung Neoplasms
Mice
Mice, Inbred C57BL
Neoplasm Metastasis
Vaccines

Source PubMed

Download CSV of topics

References60

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
11914279Successful immunotherapy of murine melanoma metastases with 7-thia-8-oxoguanosine.Clin Exp Metastasis1991https://conductscience.org/library/papers/1914279PubMed
28453674In vivo activation of natural killer cells and priming of IL-2 responsive cytolytic cells by loxoribine (7-allyl-8-oxoguanosine).Cell Immunol1993https://conductscience.org/library/papers/8453674PubMed
33263900Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases.Cancer Res1988https://conductscience.org/library/papers/3263900PubMed
43584981Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immunity.J Immunol1987https://conductscience.org/library/papers/3584981PubMed
5221611Mechanism of rejection of virus persistently infected tumor cells by athymic nude mice.J Exp Med1979https://conductscience.org/library/papers/221611PubMed
62512580Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity.Proc Natl Acad Sci U S A1989https://conductscience.org/library/papers/2512580PubMed
77061177In vivo reduction of NK activity with anti-NK 1 serum: direct evaluation of NK cells in tumor clearance.Int J Cancer1982https://conductscience.org/library/papers/7061177PubMed
86176669Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.J Exp Med1982https://conductscience.org/library/papers/6176669PubMed
9953987Tumoricidal properties of mouse macrophages activated with mediators from rat lymphocytes stimulated with concanavalin A.Cancer Res1976https://conductscience.org/library/papers/953987PubMed
101389903Effective in vivo induction of lymphokine-activated killer (LAK) cells by pretreatment with a streptococcal preparation, OK-432.Biotherapy1992https://conductscience.org/library/papers/1389903PubMed
112452203Activation of murine natural killer cells and macrophages by 8-bromoguanosine.J Immunol1988https://conductscience.org/library/papers/2452203PubMed
121693058Roles of interferon and natural killer cells in the antiviral activity of 7-thia-8-oxoguanosine against Semliki Forest virus infections in mice.Antiviral Res1990https://conductscience.org/library/papers/1693058PubMed
132297770Interleukin 1 as an adjuvant for active specific immunotherapy in a murine tumor model.Cancer Res1990https://conductscience.org/library/papers/2297770PubMed
142137327Successful combination immunotherapy for the generation in vivo of antitumor activity with anti-CD3, interleukin 2, and tumor necrosis factor alpha.Arch Surg1990https://conductscience.org/library/papers/2137327PubMed
153262772Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes.J Natl Cancer Inst1988https://conductscience.org/library/papers/3262772PubMed
161346654Progress and prospects for human cancer vaccines.J Natl Cancer Inst1992https://conductscience.org/library/papers/1346654PubMed
171860616Tumor vaccines.FASEB J1991https://conductscience.org/library/papers/1860616PubMed
182679456Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.Ann Surg1989https://conductscience.org/library/papers/2679456PubMed
192512355Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.J Immunol1989https://conductscience.org/library/papers/2512355PubMed
201701343Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy.Cancer Res1990https://conductscience.org/library/papers/1701343PubMed

See all 60 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 22 citations.

PMIDTitleJournalYearIn PapersSource
34058283Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants.Adv Drug Deliv Rev2021https://conductscience.org/library/papers/34058283PubMed
32203790Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes.Eur J Med Chem2020https://conductscience.org/library/papers/32203790PubMed
31835892Transcriptomic Analyses Revealed Systemic Alterations in Gene Expression in Circulation and Tumor Microenvironment of Colorectal Cancer Patients.Cancers (Basel)2019https://conductscience.org/library/papers/31835892PubMed
30568763The emerging chemical patterns applied in predicting human toll-like receptor 8 agonists.Medchemcomm2018https://conductscience.org/library/papers/30568763PubMed
28620298Anti-tumor Activity of Toll-Like Receptor 7 Agonists.Front Pharmacol2017https://conductscience.org/library/papers/28620298PubMed
23151919Therapeutic applications of nucleic acids and their analogues in Toll-like receptor signaling.Molecules2012https://conductscience.org/library/papers/23151919PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8306370

GET https://conductscience.org/api/papers/v1/8306370/references?page=2